Job Recruitment Website - Recruitment portal - Wuhan yuanda medicine group sales company sales company

Wuhan yuanda medicine group sales company sales company

Wuhan Yuanda Pharmaceutical Group Sales Branch is the sales platform of China Yuanda Pharmaceutical Division, which is responsible for promoting the professional pharmaceutical products of its enterprises. Wuhan tiantianming pharmaceutical co., ltd is a wholly-owned subsidiary of Wuhan yuanda pharmaceutical group, which was established in 1996. It is a national key ophthalmic drug production base and a high-tech enterprise supported by the state.

Wuhan Yuanda Sales Branch is a professional sales company specializing in ophthalmology and cardiovascular products under Wuhan Yuanda Pharmaceutical Group! The company has a strong and competitive professional sales team, and its marketing network covers the whole country, with offices in all provinces, municipalities and autonomous regions except Taiwan Province Province. The company's product line is extensive and far-reaching, and it is a new special product group with Bainaiting, Nuojia, Tiantianming series and cardiovascular product line as the core. There are 6 national second-class new drugs, 4-class new drugs 1 1, 8 new products to be listed soon, and 6 varieties under research1. Otolaryngology products alone contain 22 varieties in 5 categories, and the products are unique.

Among them, the famous brand Bai Neiting series created a classic in the history of cataract medication, which went down in history and lasted for a long time. It also has the exclusive right to use trademarks and won many provincial silver medals. In 2003, the new products Bingzhen Mu Qing and Bingzhen Hair Removing Eye Drops were approved by the word "Zhun" and entered the catalogue of over-the-counter (OTC traditional Chinese medicine preparations), which was well recognized by consumers.

In 2004, the internationally advanced novel platelet membrane glycoprotein GP Ⅱ b/Ⅲ a receptor antagonist "Xin Weining" (tirofiban hydrochloride and sodium chloride injection) was officially launched, which filled the gap of domestic antiplatelet preparations.